The Pharma Data

JUNE 12, 2025

The data were revealed during an oral presentation (S137) at the 2025 European Hematology Association (EHA) Congress in Vienna, reflecting ongoing progress in developing new treatment options for patients battling this aggressive hematologic malignancy.

Treatment 40

Treatment Small Molecule Therapies Trials 40

Drug Target Review

JUNE 16, 2025

Targeted drug delivery and therapeutic development MSI offers significant advantages for those developing small molecule therapeutics. 7 In immune therapies, MSI helps monitor immune-cell distribution and off-target effects, optimising therapeutic strategies and improving patient outcomes. For instance, Cheng et al.

Drugs 52

Drugs Organic Chemistry Laboratories Pharmaceuticals 52

BioPharma Drive: Drug Pricing

JULY 8, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. Drugmakers are working to coopt this process with targeted therapies. You can unsubscribe at anytime.

Targeted Protein Degradation 144

Targeted Protein Degradation Small Molecule Disease Therapies 144

New Drug Approvals

APRIL 2, 2025

1] [2] It is a non- opioid , small-molecule analgesic that works as a selective inhibitor of Na v 1.8 1] [2] It is a non- opioid , small-molecule analgesic that works as a selective inhibitor of Na v 1.8 The application received Breakthrough Therapy , Fast Track and Priority Review designations by the FDA.

FDA 62

FDA Therapies Trials Treatment 62

The Pharma Data

JUNE 9, 2025

The acceptance, which follows the CDE’s grant of Priority Review status in May, represents an accelerated regulatory pathway for what may become the first approved systemic therapy for TGCT in China. Pimicotinib: A Promising CSF-1R Inhibitor Pimicotinib is an investigational small molecule developed by Abbisko Therapeutics Co.,

Treatment 40

Treatment Therapies Small Molecule Marketing 40

New Drug Approvals

MAY 26, 2025

Ervogastat CAS 2186700-33-2 Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis (FAST TRACK – U.S.) 2-[5-[(3-Ethoxy-2-pyridinyl)oxy]-3-pyridinyl]- N -[(3 S )-tetrahydro-3-furanyl]-5-pyrimidinecarboxamide ( S )-2-(5-((3-Ethoxypyridin-2-yl]oxy]pyridin-3-yl)- N -(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide PF 06865571 BSOIY5AKQW 407.4

Small Molecule 62

Small Molecule Production Trials Drugs 62

Drug Patent Watch

JANUARY 13, 2025

billion by 2025, growing at a CAGR of 34.2% from 2020 to 2025[1]. Oncology: Expanding Access to Life-Saving Treatments In the field of oncology, biosimilars have made significant inroads, particularly in supportive care and targeted therapies. The global biosimilars market is projected to reach $69.4

Biosimilars 61

Biosimilars Marketing Treatment Small Molecule 61

New Drug Approvals

APRIL 18, 2025

2] The US Food and Drug Administration (FDA) granted the application for crinecerfont fast track , breakthrough therapy , orphan drug , and priority review designations. [2] Retrieved 25 January 2025. New Drug Therapy Approvals 2024 (PDF). January 2025. Archived from the original on 21 January 2025. 1 October 2024.

FDA 62

FDA FDA Approval Drugs Trials 62

New Drug Approvals

JULY 6, 2025

It is a small molecule delivered orally. [1] “Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine” Nature Communications. mmol) was added tert-butyl piperidin-4-ylcarbamate (841 mg, 98% Wt, 1.2 mmol) and DIPEA (1.19 mL, 3 Eq, 10.3 14 (1): 962. Bibcode : 2023NatCo.14.962Z.

Small Molecule 62

Small Molecule Pharmaceuticals Production Drugs 62

Alta Sciences

APRIL 24, 2025

Case Study: How Altasciences Overcame Pharmacological Challenges in a GLP-1 IND-Enabling Study pmjackson Thu, 04/24/2025 - 21:43 For emerging therapies with pronounced pharmacological effects, thoughtful study design is critical to ensuring reliable and interpretable data. This blog was originally published in April 2025.

Small Molecule 52

Small Molecule Pharmacokinetics Treatment Compliance 52

BioPharma Drive: Drug Pricing

JULY 14, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. It’ll also boost investments in U.S. drug production.

Production 152

Production Drugs Therapies Clinical Trials 152

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Small molecule GLP1s?

Small Molecule 143

Small Molecule Trials Therapies Disease 143

New Drug Approvals

JUNE 26, 2025

Acoltremon AR-15512 CAS 68489-09-8 WeightAverage: 289.419 Monoisotopic: 289.204179113 Chemical FormulaC 18 H 27 NO 2 FDA 2025, 5/28/2025, To treat the signs and symptoms of dry eye disease Tryptyr WS-12 WS 12 (1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(propan-2-yl)cyclohexane-1-carboxamide Fema No. 29 May 2025. 28 May 2025.

FDA 48

FDA Small Molecule Clinical Trials FDA Approval 48

The Pharma Data

JANUARY 19, 2021

TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. Its lead candidate is CLN-081, an oral small molecule designed to be a next-generation, irreversible EGFR inhibitor.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

New Drug Approvals

APRIL 30, 2025

New Drug Therapy Approvals 2024 (PDF). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025. ^ “Novel Drug Approvals for 2024” U.S. 1] [2] Levacetylleucine is a modified version of the amino acid leucine. [1] 1] It is the L -form of acetylleucine. 25 September 2024.

FDA 62

FDA FDA Approval Disease Trials 62

The Pharma Data

JANUARY 4, 2021

SENS-401 has demonstrated highly encouraging efficacy in preclinical models and we are excited to progress this small molecule towards clinical trials to address this significant unmet medical need in cancer patients undergoing cisplatin treatment. About Sensorion. www.sensorion-pharma.com.

Clinical Trials 40

Clinical Trials Small Molecule Therapies Treatment 40

The Pharma Data

DECEMBER 12, 2020

Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio . Rare diseases is a high-growth therapy area with rapid innovation and significant unmet medical need. Dedicated rare disease unit to be headquartered in Boston.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

JANUARY 10, 2021

In 2019, we introduced Vision 3×3, the company’s strategic roadmap through 2025, to build a leading biopharma company by achieving sustainable growth through multiple approaches. TransCon molecules have three components: an unmodified parent drug, an inert carrier that protects it, and a linker that temporarily binds the two.

Clinical Trials 40

Clinical Trials Clinical Development Small Molecule Trials 40

Drug Target Review

MAY 31, 2024

Incredible advances in machine learning-driven tools allow us to predict the 3D structure of previously unsolved proteins, unlocking the power of structure-based drug design for drugging these targets, and most recently, the ability to predict protein assemblies, which contain both the protein and putative small molecule binders.

Organic Chemistry 45

Organic Chemistry Computational Chemistry Small Molecule Disease 45

New Drug Approvals

SEPTEMBER 13, 2024

2] [3] [4] A regulatory application for approval of the medication is expected to be submitted by 2025. [2] 19] As of 2016, aticaprant has reached phase II clinical trials as an augmentation to antidepressant therapy for treatment-resistant depression. [20] 2] Aticaprant is taken by mouth. [1] nM vs. 24.0 mg and 82% for 25 mg. [15]

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

The Pharma Data

FEBRUARY 4, 2021

AbbVie announced positive top-line results from the Phase 3 ADVANCE and MOTIVATE studies, which evaluated the efficacy and safety of Skyrizi (risankizumab) for induction therapy in adult patients with moderate to severe Crohn’s disease (CD). AbbVie and Frontier Medicines, Corp., AbbVie and Frontier Medicines, Corp.,

Production 52

Production Clinical Trials International Small Molecule 52

The Pharma Data

JUNE 11, 2025

Their goal is to pinpoint novel targets that could be modulated by small molecules or biologics to restore healthy cardiac function or prevent further deterioration in at-risk patients. The research will build upon an established cardiomyocyte platform developed during the initial phase of the collaboration.

Drug Research 40

Drug Research Research Small Molecule Drugs 40

The Pharma Data

JANUARY 6, 2021

The new site will be built within the vicinity of an existing Fujifilm site, and is scheduled to begin operations in the spring of 2025. “We are uniquely placed to support our customer supply chain needs providing end to end services from small to large scale bulk drug substance production, through to fill-finish and final packing.”

Packaging 52

Packaging Small Molecule Production FDA Approval 52

BioPharma Drive: Drug Pricing

JUNE 23, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Influenza A virus" [Micrograph]. Retrieved from Flickr. His research, writing offer clues.

Drugs 264

Drugs Virus Therapies FDA 264

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

BioPharma Drive: Drug Pricing

JUNE 12, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. We urge the Senate to find a way to address the pill penalty in reconciliation.

Small Molecule 130

Small Molecule Packaging Therapies Pharmacy 130

LifeSciVC

JANUARY 21, 2025

While many early-stage private VCs (and especially those participating in recent M&A) are feeling good going into 2025, public investors lamented the poor performance of public portfolios and indices. overall sentiment was bifurcated. Herculean Clinical Impact: What Cant Incretins Do?! While some of these potential competitors (e.g.,

Trials 130

Trials Small Molecule Marketing Disease 130

Covalent Modifiers

JANUARY 13, 2025

Farrag, Yoshimasa Kawaguchi, Kazuo Nagasawa, Tasuku Honjo, Kenji Chamoto, and Motonari Uesugi Journal of the American Chemical Society 2025 DOI: 10.1021/jacs.4c17837 Combination therapies with small molecules have also been explored, but their clinical implementation has been met with significant challenges.

Production 147

Production Small Molecule Therapies 147

Alta Sciences

MARCH 27, 2025

Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category pmjackson Thu, 03/27/2025 - 19:42 Laval, Qubec, March 27, 2025 Altasciences , a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage FormNorth America category.

Small Molecule 40

Small Molecule Clinical Pharmacology Drug Development Pharmaceuticals 40

Drug Target Review

MAY 30, 2025

Drug Target Review had the pleasure of attending SLAS Europe 2025 in Hamburg and what we saw was no mere showcase of cutting-edge tools, but a clear snapshot of where drug discovery is heading. So what really stood out at SLAS 2025? You can put everything into one platform, and multiple people can engage with the data, she explained.

Small Molecule 52

Small Molecule Drugs Laboratories Engineering 52

LifeSciVC

FEBRUARY 18, 2025

Despite recent progress with AAV Gene Therapy and Antibody-Oligonucleotide Conjugates, a broad range of muscular dystrophies are still untreatable, and collectively represent an enormous unmet medical need. First, they provide guidance for the design and refinement of micro-dystrophin gene therapy constructs for DMD. 2024), Wan et al.

Small Molecule 79

Small Molecule Therapies FDA Approval Drug Development 79

Drug Target Review

APRIL 11, 2025

Drug development is hampered by high costs, long timelines and a low probability of success and complex therapies exacerbate these challenges. Traditional drugs for eye diseases like glaucoma are small molecules delivered by simple eye drops. 2024 [cited 2025 Feb 7]. Velez (2025). Lifescienceleader.com.

Clinical Development 97

Clinical Development Drugs Pharmaceuticals Clinical Trials 97

Drug Target Review

APRIL 25, 2025

3 These models are pivotal for offering key predictive insights into the clearance of metabolically stable small molecules, maintaining phase I and II metabolic activities for up to four weeks. 9,10 According to IQ-MPS recommendations, liver-on-chip systems can differentiate between toxic and non-toxic small molecule analogues.

Clinical Development 52

Clinical Development Small Molecule Drugs FDA Approval 52

New Drug Approvals

MAY 27, 2025

2025 Apr 1:10915818251327963. ETRIPAMIL CAS 1593673-23-4 AS ACETATE 512.64 ETRIPAMIL CAS 1593673-23-4 AS ACETATE 512.64 Milestone Pharmaceuticals Announces USAN Approval of Generic Name Etripamil for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia. [3]. Ascah A, et al. Int J Toxicol.

Pharmaceuticals 67

Pharmaceuticals Small Molecule Pharmacokinetics Treatment 67

New Drug Approvals

MAY 11, 2025

Retrieved 17 April 2025. Jump up to: a b New Drug Therapy Approvals 2023 (PDF). 2] [5] It is taken by mouth. [2] 5] Omaveloxolone was approved for medical use in the United States in February 2023, [2] [5] [6] [7] [8] and in the European Union in February 2024. [3] 9] SYNTHESIS PATENT Sheikh, AY et al. 2] [5] It is taken by mouth. [2]

FDA 57

FDA FDA Approval Disease Production 57

New Drug Approvals

APRIL 25, 2025

OCTADECA-15(18),17-DIEN-10-YL)BUT-3-EN-1-YL) (2S)-2-AMINO-3-METHYLBUTANETHIOATE Molecular Weight 581.75

Small Molecule 62

Small Molecule International Therapies Trials 62

New Drug Approvals

APRIL 16, 2025

“Therapy for Alzheimer’s disease: Missing targets and functional markers?” “Versatile nanomaterials for Alzheimer’s disease: Pathogenesis inspired disease-modifying therapy” Journal of Controlled Release. Kg of androst-5-en-17-one-3,7-diol, 23.8 Kg 1,1,1,3,3,3-hexamethyldisilazane (HMDS) and 0.7

Disease 62

Disease Clinical Trials Pharmaceuticals Trials 62